Clinically silent corticotroph tumors of the pituitary gland

OBJECTIVE: To determine the clinical presentation, imaging characteristics, microscopic and ultrastructural characteristics, and treatment outcomes of patients with clinically silent pituitary corticotroph adenomas. METHODS: All silent corticotroph adenomas diagnosed at the Mayo Clinic duri ng the years 1975 through 1997 were selected from the files of the Mayo Tis sue Registry. RESULTS: We studied 23 cases, occurring in 16 male and 7 female patients (a ge range, 11-79 yr; mean age, 48 yr), who presented with headaches (50%), v isual field defects (61%), extraocular muscle paresis (13%), hypopituitaris m (26%), and galactorrhea/amenorrhea (43%/29% of the female patients). No p atients exhibited clinical hypercortisolism. All tumors were macroadenomas (2.4 +/- 0.8 cm; range, 1.5-4.0 cm) and exhibited suprasellar extension in 87% of the cases and hemorrhage, necrosis, and/or cystic changes in 61 %. A ll tumors stained were variably periodic acid-Schiff-, adrenocorticotropic hormone-, and beta-endorphin-positive, particularly Subtype 1 lesions. Ultr astructural classification was performed in 19 cases. In a comparison of Su btype I and II tumors, differences were observed with respect to sex (male/ female, 1.4:1 versus 6:1), preoperative hyperprolactinemia (5 of 16 versus 0 of 6 cases), preoperative hypopituitarism (9 of 16 versus 5 of 7 cases), radiographic or gross invasion (7 of 16 versus 5 of 7 cases), and partial o r total postoperative pituitary failure (6 of 16 versus 6 of 6 cases). The overall median postoperative follow-up period was 4.9 years (range, 0.3-16. 6 yr); 54% of the patients had persistent or recurrent tumors. CONCLUSION: Clinically silent corticotroph adenomas behave in an aggressive manner and are characterized by the following: lack of clinical signs or s ymptoms of Gushing's syndrome and normal cortisol levels; no or only minor elevations of serum adrenocorticotropic hormone levels; macroadenomas with hemorrhagic infarction; and presentation dominated by mass effect symptoms. The high persistence/recurrence rate underscores the need for long-term fo llow-up.